H1 2021 financial results

Lundbeck continues to deliver solid growth for strategic brands and the financial guidance range has been updated

This is Lundbeck

We are one of the only pharmaceutical companies in the world focusing exclusively on brain diseases, and we’re set apart by our specialization.

About Us

With more than 70 years of neuroscience expertise, Lundbeck has developed and commercialized some of the world's most widely prescribed therapies for brain diseases.

Our Science

LATEST NEWS

18 August, 2021 Corporate Release
Lundbeck continues to deliver solid growth for strategic brands and the financial guidance range has been updated
04 August, 2021 Feature
Lundbeck enters strategic research collaboration with Rgenta Therapeutics on therapies targeting RNA
22 July, 2021 Feature
What do you mean brain health?

See All News

Come join us in making a difference to patients worldwide.

Job Opportunities

Explore the latest financial developments at Lundbeck.

Investors

a better life for people with brain diseases

At Lundbeck, we see patients as people and are committed to support the person behind the disease.

Patients

Partnering

The complexity of brain diseases requires a concerted effort. We are committed to develop new and better treatment options from innovations born in house or externally.

jason F. houston on working at Lundbeck

Advocacy Makes the Difference

See All Stories

Lundbeck at a glance

100

countries where our products are sold

5,600

employees supporting our purpose

1915

year Lundbeck was founded

A Strange Dream

A Small Caterpillar Taking Cover Under a Leaf

So Perfect, So Vulnerable